through 'in-bone micro-pharmacies' targeting compromised bone bdiology
Complex orthopedic infections and large bone defects remain among the most difficult challenges in musculoskeletal medicine. The current standard of care often requires two or more surgical procedures combined with prolonged systemic antibiotic therapy.
This approach increases operating room utilization, extends recovery timelines, exposes patients to systemic side effects, and significantly increases total episode-of-care costs for hospitals and healthcare systems.
Severe traumatic fractures frequently present with contaminated bone defects and a high risk of infection. Effective local infection control combined with structural bone repair is critical for limb salvage.
Persistent bone infections often require multiple surgeries, prolonged hospitalization, and long-term antibiotic therapy, with high recurrence rates and significant healthcare costs.
Infections around joint replacements are among the most devastating complications in orthopedic surgery, frequently requiring staged revision procedures and extended treatment timelines.
Failure of bone healing combined with infection represents a complex clinical scenario where both infection eradication and biological bone regeneration must be addressed simultaneously.
JWP GmbH is transforming orthopedic surgery by creating 'in-bone micro-pharmacies', a platform designed for scalable regulatory pathways and broad orthopedic indications, where surgeons can balance infection management, structural repair, and regeneration within a single treatment strategy.
We combine advanced nanomedicine and pharmacological delivery technologies with clinically proven allograft biology, creating solutions aligned with surgeon workflow, hospital economics, and regulatory feasibility.
Why now
Orthopedic infections and complex bone defects are rising globally due to aging populations, increasing trauma cases, and the rapid growth of joint replacement surgeries. At the same time, antimicrobial resistance and hospital cost pressures are forcing a shift toward more efficient surgical solutions. JWP’s drug-eluting bone graft platform addresses this convergence by enabling infection control and bone regeneration within a single surgical strategy.
JWP collaborates with leading academic and clinical institutions including RWTH Aachen University and University Hospital Aachen. Early engagement with orthopedic surgeons and trauma centers in Europe and the United States supports clinical translation and ensures alignment with real surgical workflows.
JWP GmbH is transforming orthopedic surgery by creating 'in-bone micro-pharmacies', a platform that
combines localized disease control with active bone regeneration — eliminating the current costly
standard of care consisting of 2-stage surgeries and replacing it with 1-stage treatment.
We merge
cutting-edge nanomedicine and pharmacological technologies with clinically proven allograft biology
to redefine orthopedic surgery.
~$0B
Total Addressable Market (TAM)
~$0B
Serviceable Available Market (SAM)
0+
US / EU new patients annually
~6% CAGR across 5 orthopedic indications
Partnered with Aachen University Hospital for prototype development
Collaborating with Prof. Dr. Dr. Twan Lammer's group to advance drug-eluting bone graft prototypes.
15 December 2025
1st Place at BioRiver Boost Competition
Winner of the 12th BioRiver Boost, one of Germany's premier industry-led Biotech/MedTech StartUp competitions.
11 December 2025
Top Prize at ZEBRA Accelerator
Awarded Top Prize in the Investment MasterClass category at the ZEBRA Accelerator program.
04 December 2025
State Innovative Entrepreneurs Grant Award
Dr. Wa'el Al Rawashdeh awarded the prestigious State Innovative Entrepreneurs Grant to accelerate development of our regenerative technologies.
01 October 2025